anti-CD20 mAb-IFN alpha fusion protein (UCLA)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD20 mAb-IFN alpha fusion protein (UCLA)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsInterferon alpha ligand

TargetsInterferon alphaB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of California, Los Angeles

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A